Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
Most pathogens either invade the body or establish infection in mucosal tissues and represent an enormous challenge for vaccine development by the absence of good mucosal adjuvants. A proteoliposome-derived adjuvant from Neisseria meningitidis serogroup B (AFPL1, Adjuvant Finlay Proteoliposome 1) and its derived cochleate form (Co, AFCo1) contain multiple pathogen-associated molecular patterns as immunopotentiators, and can also serve as delivery systems to elicit a Th1-type immune response. The present studies demonstrate the ability of AFPL1and AFCo1 to induce mucosal and systemic immune responses by different mucosal immunizations routes and significant adjuvant activity for antibody responses of both structures: a microparticle and a nanoparticle with a heterologous antigen. Therefore, we used female mice immunized by intragastric, intravaginal, intranasal or intramuscular routes with both structures alone or incorporated with ovalbumin (OVA). High levels of specific IgG antibody were detected in all sera and in vaginal washes, but specific IgA antibody in external secretions was only detected in mucosally immunized mice. Furthermore, antigen specific IgG1 and IgG2a isotypes were all induced. AFPL1 and AFCo1 are capable of inducing IFN-gamma responses, and chemokine secretions, like MIP-1alpha and MIP-1beta. However, AFCo1 is a better alternative to induce immune responses at mucosal level. Even when we use a heterologous antigen, the AFCo1 response was better than with AFPL1 in inducing mucosal and systemic immune responses. These results support the use of AFCo1 as a potent Th1 inducing adjuvant particularly suitable for mucosal immunization.
Campo
Judith Del
JD
Immunology Department, Finlay Institute, PO Box 16017, Havana, Cuba. judithc@finlay.edu.cu
Zayas
Caridad
C
Romeu
Belkis
B
Acevedo
Reinaldo
R
González
Elizabeth
E
Bracho
Gustavo
G
Cuello
Maribel
M
Cabrera
Osmir
O
Balboa
Julio
J
Lastre
Miriam
M
D000281:Administration, Intranasal; D000282:Administration, Intravaginal; D000818:Animals; D002478:Cells, Cultured; D003840:Deoxycholic Acid / Q000008:administration & dosage / Q000276:immunology; D004492:Edetic Acid / Q000008:administration & dosage / Q000276:immunology; D005260:Female; D018928:Immunity, Mucosal / Q000187:drug effects / Q000276:immunology; D007114:Immunization / Q000379:methods*; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009092:Mucous Membrane / Q000187:drug effects / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D011510:Proteolipids / Q000008:administration & dosage* / Q000276:immunology*
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D011510:Proteolipids; C020485:proteoliposomes; D003840:Deoxycholic Acid; D004492:Edetic Acid